News
Epigenomics: Aktie crasht -77% nach US-Schock
Die staatliche US-Krankenversicherung Centers for Medicare & Medicaid Services (CMS) lehnt Epi proColon ab. Das geht aus einem vorläufigen Erstattungsvorschlag hervor. Die Schockwellen sind in der E
Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that detailed results of the
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical
Quantum Genomics to receive up to $50 million in upfront and milestone payments plus double-digit royalties on sales
Qilu Pharmaceutical to receive an exclusive license to develop and commercialize
IMV Inc. Re-establishes At-the-Market Facility
IMV Inc. (TSX: IMV; NASDAQ: IMV) (the "Company" or “IMV”), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated October 16
Charles River Laboratories Adds George Llado to Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of George Llado, Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, Inc., to
Medigene AG: Three Medigene poster presentations at SITC Annual Meeting
Planegg/Martinsried (15.10.2020) - Scientists of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell
Medigene AG: Drei Poster Präsentationen von Medigene auf dem SITC Annual Meeting
Planegg/Martinsried (15.10.2020) - Wissenschaftler der Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen mit klinischen Projekten fokussiert auf die
NeutriSci betritt mit dem US-Bundesstaat Washington den Markt mit den zweithöchsten Cannabis-Umsätzen weltweit
Vancouver (British Columbia), 15. Oktober 2020 - NeutriSci International Inc. (TSX-V: NU, OTCQB: NRXCF, Frankfurt: 1N9) („NeutriSci“ oder das „Unternehmen“, ein innovatives
NeutriSci Enters the Second Highest Grossing Market with New Distribution in the State of Washington
Vancouver, British Columbia – October 15, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
Biomarkers Associated With Clinical Response in Patients With r/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented at the Upcoming SITC Annual Meeting
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that
BOIRON : Projected timetable of the next publications and events 2021
The projected timetable of the next publications and events for the year 2021 is the following one:
Publications Date of publication (after market closing) Information meetings
Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB
Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that a patient has passed away
Sensorion Obtains €3 Million Loans, Including €2 Million Guaranteed by the French Government (PGE) and €1 Million as RDI Loan Through Bpifrance
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced four poster
EnWave Signs Technology Evaluation and License Option Agreement with American Industrial Hemp Producer
Vancouver, B.C., October 14, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced today
EnWave unterzeichnet Technologiebewertungsabkommen inklusive Lizenzoptionen mit amerikanischem Industriehanfproduzenten
Vancouver, B.C., 14. Oktober 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab
Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced Time Is Nephrons, the first-ever lupus nephritis (LN) disease-state awareness campaign for
QIAGEN veröffentlicht starke vorläufige Zahlen für das dritte Quartal 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gibt vorläufige Zahlen für Umsatz und bereinigtem Gewinn pro Aktie für das dritte Quartal 2020 bekannt.
Der Nettoumsatz stieg sowohl zu
QIAGEN reports strong preliminary results for third quarter of 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today preliminary sales and adjusted earnings per share (EPS) results for the third quarter of 2020.
Net sales grew 26% at actual
Charles River Laboratories Schedules Third-Quarter 2020 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2020 financial results on Thursday, October 29th, before the market opens. A conference call has been scheduled
Evotec: Jetzt ist auch Abu Dhabi an Bord
Wie das Hamburger Biotechnologieunternehmen Evotec (WKN: 566480) heute früh vermeldete, investieren die Mubadala Investment Company sowie die Novo Holdings 250 Millionen Euro im Rahmen einer
Formycon: Sensationelle News!
Wie der Biosimilar-Spezialist Formycon (WKN: A1EWVY) heute früh vermeldete, erhält man Fördermittel in Höhe von 290.000 Euro für das Projekt "Charakterisierung von ACE2-IgG-Konstrukten", einem
Sirona Biochem Signs Agreement with Global Pharmaceutical Company for Clinical Trial of its Novel Skin Care Compound TFC-1067
Vancouver, Canada - October 13, 2020 - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that it has signed an agreement with a top 10 global
Sirona Biochem unterzeichnet Vertrag mit weltweit agierendem Pharmaunternehmen für klinische Studie zu seinem neuartigen Hautpflegewirkstoff TFC-1067
Vancouver, Kanada - 13. Oktober 2020 - Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (US-OTC: SRBCF) („Sirona“) freut sich bekannt zu geben, dass man mit einem der 10 führenden weltweit